← Back to Skills Marketplace

Amgen Biotech

Name: Amgen Biotech
Author: hanxueyuan

by hanxueyuan · GitHub ↗ · v1.0.0 · MIT-0

cross-platform ✓ Security Clean

Downloads

Stars

Active Installs

Versions

Install in OpenClaw

/install amgen-biotech

Description

Amgen pioneers biotech with key drugs EPO and Neupogen, focusing on oncology, cardiovascular, and inflammation therapies with biologics-based revenue.

README (SKILL.md)

Amgen

历史时间线

1980: William K. Bowes Jr.、Franklin P. Johnson 等人在加州创立 Applied Molecular Genetics
1983: 更名为 Amgen（Applied Molecular Genetics 的缩写）
1989: Epogen (EPO) 获批，成为首个十亿美元级生物药
1991: Neupogen (G-CSF) 获批
2000: 以 230 亿美元收购 Immunex
2013: 以 104 亿美元收购 Onyx Pharmaceuticals
2019: 以 340 亿美元收购 Horizon Therapeutics
2024: 专注于肿瘤学、心血管和炎症领域

商业模式

以生物制剂（biologics）为核心，主要治疗领域：肿瘤学、心血管疾病、炎症和骨骼健康。收入模式以处方药销售为主，专利期内的药物贡献绝大部分利润。

护城河分析

生物制剂的制造复杂性构成极高进入壁垒。EPO 和 Neupogen 虽是老药但仍贡献稳定收入。Horizon Therapeutics 收购带来的罕见病药物组合拓展了产品管线。

关键数据

2024 年营收约 280 亿美元。研发支出约 40 亿美元/年。全球员工约 25,000 人。拥有 20+ 款已上市药物。

有趣事实

Amgen 是第一家将基因工程技术商业化应用于药物开发的公司之一。EPO 的开发引发了体育史上最著名的兴奋剂丑闻之一 — 环法自行车赛中 Lance Armstrong 的 EPO 使用。Amgen 的名字 'Applied Molecular Genetics' 后来被缩短为 'Amgen'，因为原名太长了。

Usage Guidance

This skill appears safe from a security perspective. Treat it as a brief reference note about Amgen; verify business or historical facts independently if accuracy matters.

Capability Analysis

Type: OpenClaw Skill Name: amgen-biotech Version: 1.0.0 The skill bundle contains purely informational content regarding the history, business model, and market position of the biotechnology company Amgen. There is no executable code, network activity, or suspicious instructions within SKILL.md or _meta.json.

Capability Assessment

✓ Purpose & Capability

The SKILL.md content is a short company/industry overview matching the stated Amgen biotech purpose.

✓ Instruction Scope

The artifact provides reference information and read-when guidance; it does not instruct the agent to run tools, change goals, or take actions on the user's behalf.

✓ Install Mechanism

There is no install spec and no code files, so there is no observed package, script, or runtime installation risk.

✓ Credentials

The skill declares no required binaries, environment variables, credentials, config paths, or OS-specific access.

✓ Persistence & Privilege

No persistence, background execution, account access, local file indexing, or privilege use is shown in the provided artifacts.

How to Use

Make sure OpenClaw is installed (local or Docker)
Run the install command in chat: /install amgen-biotech
After installation, invoke the skill by name or use /amgen-biotech
Provide required inputs per the skill's parameter spec and get structured output

Version History

v1.0.0

- 初始版本发布，提供 Amgen 公司的详细介绍和发展历史。 - 涵盖 EPO 与 Neupogen 两款标志性药物的商业化与行业影响。 - 描述 Amgen 的商业模式、护城河分析及关键财务与运营数据。 - 增加有趣事实，包括公司名称由来及 EPO 相关历史事件。

Metadata

Slug amgen-biotech

Version 1.0.0

License MIT-0

All-time Installs 0

Active Installs 0

Total Versions 1

Frequently Asked Questions

What is Amgen Biotech?

Amgen pioneers biotech with key drugs EPO and Neupogen, focusing on oncology, cardiovascular, and inflammation therapies with biologics-based revenue. It is an AI Agent Skill for Claude Code / OpenClaw, with 36 downloads so far.

How do I install Amgen Biotech?

Run "/install amgen-biotech" in the OpenClaw or Claude Code chat to install it in one step — no extra setup required.

Is Amgen Biotech free?

Yes, Amgen Biotech is completely free, licensed under MIT-0. You can download, install and use it at no cost.

Which platforms does Amgen Biotech support?

Amgen Biotech is cross-platform and runs anywhere OpenClaw / Claude Code is available (cross-platform).

Who created Amgen Biotech?

It is built and maintained by hanxueyuan (@hanxueyuan); the current version is v1.0.0.

More Skills